Irodalom:
1. P. Neuhaus, H. Oettle, S. Post et al: A randomised, prospective, multicenter, phase III trial of adjuvant
chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer Journal of
Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1
Supplement), 2005: 4013
2. J.P. Neoptolemos, D.D. Stocken, H. Friess et al: ESPAC-1: Final Results of a European, Randomised
Controlled Trial to Assess the Roles of Adjuvant Chemotherapy and Adjuvant Chemoradiation in
402 Gastro Update 2007
Resectable Pancreatic Cancer Pancreatology 2003,3,209-269
3. Kalser MH, Ellenberg SS: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following
curative resection Arch Surg. 1985 Aug;120(8):899-903
4. Klinkenbijl JH,Jeekel J, Sahmoud T et al: Adjuvant radiotherapy and 5-fluorouracil after curative resection
of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract
cancer cooperative group Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4
5. Michael C. Garofalo, MD, William F. Regine, MD, and Ming T. Tan: PhD On Statistical Reanalysis,
the EORTC Trial Is a Positive Trial for Adjuvant Chemoradiation in Pancreatic Cancer Ann Surg 2006
August; 244(2): 332-333
6. W. F. Regine, K. W. Winter, R. Abrams et al: RTOG 9704 a phase III study of adjuvant pre and post
chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma Journal of
Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20
Supplement), 2006: 4007
7. B. Chauffert, F. Mornex, F. Bonnetain et al: Phase III trial comparing initial chemoradiotherapy
(intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients
with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. Journal of Clinical
Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement),
8. R. Wilkowski, H. Rau, C. Bruns et al: Randomized phase II trial comparing gemcitabine/cisplatin-based
chemoradiotherapy (CRT) to 5-FU-based CRT in patients with locally advanced pancreatic cancer.
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol 24,
No 18S (June 20 Supplement), 2006: 4038
9. Masanori Tsujie, Shoji Nakamori, Eiichi Tanaka et al: Phase I/II Trial of Hyperfractionated Accelerated
Chemoradiotherapy for Unresectable Advanced Pancreatic Cancer. Japanese Journal of Clinical
Oncology 2006 36(8):504-510;
10. C. H. Crane, S. Krishnan, V. Ranaet al: Does the Addition of Bevacizumab to Chemoradiation Prolong
Median Survival In Locally Advanced Pancreatic Cancer Patients—Journal of Clinical Oncology, 2006
ASCO Annual Meeting Proceedings
11. Crane CH, Ellis LM, Abbruzzese JLet al: Phase I trial evaluating the safety of bevacizumab with
concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol. 2006
Mar 1;24(7):1145-51
12. R. C. Krempien, M. W. Münter, C. Timke et al: Phase II study evaluating trimodal therapy with cetuximab
intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic
cancer [ISRCTN56652283] Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings
(Post-Meeting Edition).Vol 24, No 18S (June 20 Supplement), 2006: 4100
13. J. M. Pipas, B. Zaki, A. A. Suriawinata et al: Cetuximab, intensity-modulated radiotherapy (IMRT), and
twice-weekly gemcitabine for pancreatic adenocarcinoma. Journal of Clinical Oncology, 2006 ASCO
Annual Meeting Proceedings (Post-Meeting Edition). Vol 24, No 18S (June 20 Supplement), 2006: 14056
14. Maurel J, Martin-Richard M, Conill C, et al: Phase I trial of gefitinib with concurrent radiotherapy and
fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. International Journal of Radiation
Oncology Biology Physics 2006;66(5):1391-1398
15. Mornex F, Girard N, Scoazec JY et al: Feasibility of preoperative combined radiation therapy and
chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma:
The French SFRO-FFCD 97-04 Phase II trial. Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1471-8.
Epub 2006 Jun 21
16. Wilkowski R, Thoma M, Bruns C, Wagner A, Heinemann V: Chemoradiotherapy with gemcitabine
and continuous 5-FU in patients with primary inoperable pancreatic cancer. JOP. 2006 Jul 10;7(4):349-360
17. Massucco P, Capussotti L, Magnino A et al: Pancreatic resections after chemoradiotherapy for locally
advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol.
2006 Sep;13(9):1201-8
A hasnyálmirigy 403
18. Florence Huguet, Thierry André, Pascal Hammel, Pascal Artru, Jacques Balosso, Frédéric Selle,
Elisabeth Deniaud-Alexandre, Philippe Ruszniewski, Emmanuel Touboul, Roberto Labianca, Aimery
de Gramont, Christophe Louvet: Impact of Chemoradiotherapy After Disease Control With Chemotherapy
in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies Journal of
Clinical Oncology, Vol 25, No 3 (January 20), 2007: pp. 326-331
19. M. Peeters, T. Boterberg, E. Monsaert, I. Borbath, A. Demols, M. Polus, P. Scalliet, F. Berrevoet, T.
Derre, J. Van Laethem: Dose-finding study using 0xaliplatin (Ox) in combination with fixed dose
gemcitabine (Gem) and radiotherapy (RT) in patients with locally advanced pancreatic or biliary tract
cancer (PBCa). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Vol 24, No 18S
(June 20 Supplement), Abstract14028
20. C. Townsley, A. M. Brade, C. Brezden-Masley, D. Hedley, S. Gallinger, G. R. Pond, A. M. Oza, J.
Brierley, M. J. Moore: Long-term results of concurrent gemcitabine (G) and radiotherapy (GRT) for
locally advanced (LA) or high-risk resected (R) pancreatic cancer. Journal of Clinical Oncology, 2006
ASCO Annual Meeting Proceedings Vol 24, No 18S (June 20 Supplement), Abstract 4101
21. S. Roy, S. Russo, G. Black, M. A. Eloubeidi, A. Steg, D. Zelterman, M. R. Johnson, R. B. Diasio, M.
W. Saif: Upregulation of thymidine phosphorylase (TP) by radiation (XRT): Phase II study of capecitabine
(CAP) with XRT in pts with locally advanced (LA) pancreatic cancer. Journal of Clinical Oncology,
2006 ASCO Annual Meeting Proceedings Vol 24, No 18S (June 20 Supplement), Abstract 14001
22. F. Leone, E. Sperti, S. Aliberti, M. Gatti, P. Massucco, A. Magnino, R. Faggiuolo, P. Gabriele, L.
Capussotti, M. Aglietta: Phase II trial of induction GEMOX followed by a twice-weekly infusion of
gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic
cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Vol 24, No 18S (June
20 Supplement), Abstract 14019
23. L. Moureau-Zabotto, J. Phélip, P. Afchain, L. Mineur, T. André, V. Vendrely, G. Lledo, O. Dupuis, E.
Touboul, J. Balosso: Concomitant administration of weekly oxaliplatin, 5FU continuous infusion and
radiotherapy in locally advanced pancreatic cancer (LAPC): A GERCOR phase II study. Journal of
Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Vol 24, No 18S (June 20 Supplement),
Abstract 4039
24. J. Maurel, M. Martin-Richard, C. Conill, M. Sanchez, L. Petriz, A. Ginés, R. Gallego, R. Cajal, S.
Navarro, L. Fernandez-Cruz: Phase I trial of gefitinib with concurrent radiotherapy and fixed dose-rate
gemcitabine infusion, in locally advanced pancreatic cancer. Journal of Clinical Oncology, 2006 ASCO
Annual Meeting Proceedings Vol 24, No 18S (June 20 Supplement), Abstract 4105
25. Ito Y, Okusaka T, Kagami Y et al: Evaluation of acute intestinal toxicity in relation to the volume of
irradiated small bowel in patients treated with concurrent weekly gemcitabine and radiotherapy for
locally advanced pancreatic cancer. Anticancer Res. 2006 Sep-Oct;26(5B):3755-9
26. Ghassan K. Abou-Alfa, Richard Letourneau, et al: Randomized Phase III Study of Exatecan and
Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer
J. Clin. Oncol., Sep 2006; 24: 4441 – 4447.
27. V Heinemann, D Quietzsch, F Gieseler et al: Randomized Phase III Trial of Gemcitabine Plus Cisplatin
Compared With Gemcitabine Alone in Advanced Pancreatic Cancer J. Clin. Oncol., Aug 2006; 24: 3946-3952.
28. Andrew H. Ko, Elizabeth Dito, Brian Schillinger, Alan P. Venook, Emily K. Bergsland, Margaret A:
Tempero Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma
of the Pancreas. Journal of Clinical Oncology, Vol 24, No 3 (January 20), 2006: pp. 379-385
29. M Jafari, GR Varadhachary, H Xiong, D Chang, H Ozer, JL Abruzzese RA Wolff: Bi-institutional
phase II trial of gemcitabine, oxaliplatin and bevacizumab in patients with advanced pancreatic cancer.
Gastrointestinal Cancers Symposium Proceedings 19-21 Orlando 2007 Abstract No 141
30. F Kullmann, S Hollerbach, M Dollinger, J Hinke, E Endlicher: Cetuximab plus gemcitabine/oxaliplatin
(GEMOXCET) in 1st line metastatic pancreatic cancer. First results from a multicenter phase II study
Gastrointestinal Cancers Symposium Proceedings 19-21 Orlando 2007 Abstract No 128
404 Gastro Update 2007
31. Takuji Okusaka, Hiroshi Ishii, Akihiro Funakoshi, Hideki Ueno, Junji Furuse and Toshihiko Sumii A:
Phase I/II Study of Combination Chemotherapy with Gemcitabine and 5-Fluorouracil for Advanced
Pancreatic Cancer Japanese Journal of Clinical Oncology 2006 36(9):557-563
32. L. C. Garrot, A. Berkenblit, M. Goldstein, E. Florendo, J. Underhill, P. Forino, K. Stuart. Phase II trial
of capecitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma.
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Vol 24, No 18S (June 20
Supplement), Abstract 14103
33. M. M. Javle, R. V. Iyer, J. Yu, D. Q. Wilkinson, H. R. Nava, J. T. Phelan, A. M. Litwin, J. M. Haney,
J. F. Gibbs, B. W. Kuvshinoff: Phase II study of gemcitabine, capecitabine and bevacizumab for
advanced pancreatic cancer (APC) with ECOG PS 0-1. Journal of Clinical Oncology, 2006 ASCO
Annual Meeting Proceedings Vol 24, No 18S (June 20 Supplement), Abstract 4117
34. H Ueno, J Furuse, K Yamao, A Funakoshi, N Boku, S Ohkawa, A Makimoto, T Sato, T Okusaka: A
multicenter phase II study of Gemcitabine and S-1 combination therapy (GS) in patients with metastatic
pancreatic cancer Gastrointestinal Cancers Symposium Proceedings 19-21 Orlando 2007 Abstract No 148
35. M. Roach, F. Lee, I. Rabinowitz, G. Parasher, G. Heywood: Combination of irinotecan, oxaliplatin and
cetuximab for patients with metastatic pancreatic cancer. Journal of Clinical Oncology, 2006 ASCO
Annual Meeting Proceedings Vol 24, No 18S (June 20 Supplement), Abstract 14135
36. M. Milella, P. Carlini, A. Gelibter, E. Ruggeri, A. Ceribelli, M. Pino, E. Terzoli, F. Cognetti, D.
Giannarelli and E: Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (PostMeeting
Edition). Vol 24, No 18S (June 20 Supplement), 2006: 4118
Gemcitabine-based polychemotherapy for advanced pancreatic cancer (APC): Is it ready for prime time?
A pooled analysis of 3,682 patients (pts) enrolled in 12 phase III trials.
37. V Heinemann, A Hinke, S. Boeck, C Louvet: Benefit from gemcitabine-based combination treatment
in advanced pancreatic cancer: A meta-analysis of randomized trials Gastrointestinal Cancers
Symposium Proceedings 19-21 Orlando 2007 Absrtact No 129
38. K Nakachi, J Furuse, M Najima, T Okusaka, H Ishii, E Suzuki, S Shimizu, M Yoshino: Tolerability and
efficacy of standard chemotherapy with gemcitabine for elderly patients with advanced pancreatic cancer
Gastrointestinal Cancers Symposium Proceedings 19-21 Orlando 2007 Abstract No 147
39. T. V. Voorthuizen, W. L. Vervenne, E. H. Van Daalen, S. S. Phoa, D. J. Gouma, M. J. Bruno, D. J. Richel:
A randomized phase II study comparing gemcitabine plus nadroparine versus gemcitabine in patients
with locally advanced or metastatic pancreatic carcinoma: The GEMFRAX trial. Journal of Clinical
Oncology, 2006 ASCO Annual Meeting Proceedings Vol 24, No 18S (June 20 Supplement), Abstract 4112
40. U. Pelzer, A. Hilbig, J. Stieler, L. Roll, M. Stauch, B. Opitz, T. Scholten, S. Hahnfeld, B. Dörken, H. Riess,
H. Oettle: A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin
and chemotherapy (PROSPECT – CONKO 004). Journal of Clinical Oncology, 2006 ASCO Annual
Meeting Proceedings Vol 24, No 18S (June 20 Supplement), Abstract 4110
41. Ciao Max, Sao Pedro Rocha, Aurea Maria Flores: Gemcitabine doublets in advanced pancreatic cancer:
Should we move on? Journal of Clinical Oncology Vol 24 No 3 2006: pp. 327-29
42. S Boeck, K Weigang-Köhler, M Fuchs et al: Second-line chemotherapy with pemetrexed after
gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial Ann.
Onc. Jan 2007
43. H. Q. Xiong, R. A. Wolff, K. R. Hess, G. R. Varadhachary, J. C. Blais, J. L. Abbruzzese: A phase II trial
of oxaliplatin plus capecitabine (xelox) as second line therapy for patients with advanced pancreatic
cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Vol 24, No 18S (June
20 Supplement), Abstract 4119
44. B. Chue, N. Chen. Weekly paclitaxel, oxaliplatin, 5-FU and leucovorin in the treatment of metastatic
pancreatic cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings
Vol 24, No 18S (June 20 Supplement), Abstract 14146
45. A. Gelibter, M. Milella, P. Malaguti, S. De Marco, E. Ruggeri, P. Carlini, M. Pino, C. Nuzzo, C. N.
A hasnyálmirigy 405
Sternberg, F. Cognetti: Pilot study of capecitabine combined with celecoxib (CapCel) as second-line
treatment for advanced pancreatic (P) and biliary tree (BT) cancer. Journal of Clinical Oncology, 2006
ASCO Annual Meeting Proceedings Vol 24, No 18S (June 20 Supplement), Abstract 14055
46. LL. Siu, A. Awada, CH. Takimoto, M Piccart et al: Phase I Trial of Sorafenib and Gemcitabine in
Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer Clin. Cancer Res.,
Jan 2006; 12: 144 – 151.
47. JA Wallace, G Locker, S Nattam, K Kasza, K Wade-Oliver, EE Vokes: Sorafenib (S) plus Gemcitabine
(G) for advanced pancreatic cancer (PC): A phase II trial of the University of Chicago Phase II
Consortium Gastrointestinal Cancers Symposium Proceedings 19-21 Orlando 2007 Abstract No 137
48. D. A. Richards, K. A. Boehm, D. M. Waterhouse, D. J. Wagener, S. S. Krishnamurthi, A. Rosemurgy,
W. Grove, K. Macdonald, S. Gulyas, M. Clark and K. D. Dasse: Gemcitabine plus CI-994 offers no
advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results
of a phase II randomized, double-blind, placebo-controlled, multicenter study Annals of Oncology 2006
17(7):1096-1102
49. J. A. Wright, J. Osterlee, S. Fekete, Y. Lee, A. H. Young: A phase III trial of virulizin plus gemcitabine
vs. gemcitabine alone in advanced pancreatic cancer: Results of subgroup analysis. Journal of Clinical
Oncology, 2006 ASCO Annual Meeting Proceedings Vol 24, No 18S (June 20 Supplement), Abstract 4116
50. M. Ikeda, T. Okusaka, Y. Ito, H. Ueno, C. Morizane, J. Furuse, H. Ishii, M. Kawashima, Y. Kagami,
H. Ikeda: A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Vol 24, No 18S (June 20
Supplement), Abstract 14003
51. S. Ohkawa, A. Amano, M. Ueno, K. Miyakawa, K. Sugimori, K. Tanaka, M. Kida: A phase I multicentric
trial of combined chemotherapy with gemcitabine plus S-1 in patients with advanced pancreatic cancer.
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Vol 24, No 18S (June 20
Supplement), Abstract 14047
52. C. Morizane, T. Okusaka, J. Furuse, H. Ishii, H. Ueno, M. Ikeda, M. Najima, S. Hirokawa, K. Nakachi,
T. Ogura: A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Journal of
Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Vol 24, No 18S (June 20 Supplement),
Abstract 1415
53. G. Chiorean, T. Dragovich, J. T. Hamm, V. K. Langmuir, S. Kroll, D. T. +ung, A. B. Colowick, P. J.
Loehrer: Glufosfamide (GLU) plus gemcitabine (GEM) in advanced solid tumors: Phase 1 results.
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Vol 24, No 18S (June 20
Supplement), Abstract 14022
54. H. L. Kindler, K. A. Bylow, H. S. Hochster, G. Friberg, K. Micetich, G. Locker, M. Kozloff, M. Moore,
W. Sun, E. E. Vokes: A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab
(C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis.
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Vol 24, No 18S (June 20
Supplement), Abstract
55. S. S. Grubbs, P. A. Grusenmeyer, N. J. Petrelli, R. J. Gralla. Helen F. Graham: Is it cost-effective to
add erlotinib to gemcitabine in advanced pancreatic cancer? Journal of Clinical Oncology, 2006 ASCO
Annual Meeting Proceedings Vol 24, No 18S (June 20 Supplement), Abstract 6048
56. J. P. Spano, M. Moore, S. Kim, K. F. Liau, B. Hee, P. Bycott, P. Boissaye, S. Francis, D. Peters, O. Rixe:
A phase I study of Axitinib (AG-013736), a potent inhibitor of VEGFRs, in combination with gemcitabine
(GEM) in patients (pts) with advanced pancreatic cancer. Journal of Clinical Oncology, 2006 ASCO
Annual Meeting Proceedings Vol 24, No 18S (June 20 Supplement), Abstract13092
57. N. Dhillon, R. A. Wolff, J. L. Abbruzzese, D. S. Hong, L. H. Camacho, L. Li, F. Braiteh, R. Kurzrock:
Phase II clinical trial of curcumin in patients with advanced pancreatic cancer. Journal of Clinical
Oncology, 2006 ASCO Annual Meeting Proceedings Vol 24, No 18S (June 20 Supplement), Abstract 14151
58. D. L. Groteluschen, M. R. Mahoney, H. C. Pitot, D. Laheru, J. Kolesar, J. P. Thomas, C. Erlichman, K.
406 Gastro Update 2007
D. Holen: A multicenter phase 2 consortium (P2C) study of triapine in patients (pts) with advanced
adenocarcinoma of the pancreas. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings
Vol 24, No 18S (June 20 Supplement), Abstract 14118
59. E. Greeno, H. L. Kindler, M. Peeters, R. C. Trowbridge, G. Chong, J. W. Valle, B. Johnson, E. L. Allain,
H. A. Burris: A phase II study of triapine in combination with gemcitabine (G) in patients (pts) with
unresectable or metastatic pancreatic cancer (PC). Journal of Clinical Oncology, 2006 ASCO Annual
Meeting Proceedings Vol 24, No 18S (June 20 Supplement), Abstract 4123
60. R. Fahrig, D. Quietzsch, V. Heinemann, A. Liebert, M. Haenel RE: A phase II pilot trial with RP101
in advanced pancreatic carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting
Proceedings Vol 24, No 18S (June 20 Supplement), Abstract14000
61. E. Bria, P. Carlini, A. Gelibter, E. Ruggeri, A. Ceribelli, M. Pino, E. Terzoli, F. Cognetti, D. Giannarelli,
M. Milella: Current status of targeted agents in advanced pancreatic cancer (APC): A pooled analysis
of 2,361 patients (pts) enrolled in six phase III trials. Journal of Clinical Oncology, 2006 ASCO Annual
Meeting Proceedings Vol 24, No 18S (June 20 Supplement), Abstract 4126
62. G. Lopes, B. Bastos, E. Ahn, J. Quesada, M. Allison, A. Flores, A. Ribeiro, J. Levi, J. Macintyre, C.
M. Rocha-Lima: A phase II trial of capecitabine and docetaxel in patients with previously treated
pancreatic cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Vol 24, No
18S (June 20 Supplement), Abstract 14111
63. Kohei Nakachi, Junji Furuse, Hiroshi Ishii, Ei-ichiro Suzuki and Masahiro Yoshino: Prognostic Factors
in Patients with Gemcitabine-Refractory Pancreatic Cancer Japanese Journal of Clinical Oncology
published online on February 1, 2007
64. D Wong AH, Ko J, Hwang AP, Venook EK, Bergsland MA: Tempero Serum CA 19-9 decline compared
to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer
receiving fixed-dose rate gemncitabine. Gastrointestinal Cancers Symposium Proceedings 19-21
Orlando 2007 Abstract No 116
65. Vogl TJ, Schwarz W, Eichler K, et al: Hepatic intraarterial chemotherapy with gemcitabine in patients
with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: A clinical study on
maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol 2006;132(11):745-755.
66. Reni M, Bonetto E, Cordio S, et al: Quality of life assessment in advanced pancreatic adenocarcinoma:
Results from a phase III randomized trial. Pancreatology 2006;6(5):454-463.
67. S. Cascinu, L. Verdecchia, N. Valeri, R. Berardi and M. Scartozzi: New target therapies in advanced
pancreatic cancer Annals of Oncology 2006 17 (Supplement) :148-152
